Human pluripotent stem cells such as embryonic stem cells (ESCs) and induced pluripotent
stem cells (iPSCs) provide unprecedented opportunities for cell therapies against intractable …

Cell-based therapies are being developed for various neurodegenerative diseases that
affect the central nervous system (CNS). Concomitantly, the roles of individual cell types in …

Recent advances in neoantigen research have accelerated the development and regulatory
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …

CRISPR-Cas technology has revolutionized biological research and holds great therapeutic
potential. Here, we review CRISPR-Cas systems and their latest developments with an …

There is increasing evidence for a role of inflammation in Parkinson's disease. Recent
research in murine models suggests that parkin and PINK1 deficiency leads to impaired …

Improved stem cell-derived pancreatic islet (SC-islet) differentiation protocols robustly
generate insulin-secreting β cells from patient induced pluripotent stem cells (iPSCs). These …

T cells, natural killer (NK) cells, macrophages (Macs), and dendritic cells (DCs) are among
the most common sources for immune-cell-based therapies for cancer. Antitumor activity can …

The promise of human induced pluripotent stem cells (iPSCs) lies in their ability to serve as
a starting material for autologous, or patient‐specific, stem cell–based therapies. Since the …

Compelling evidence from experimental animal disease models and early-phase clinical
trials identifies the transplantation of neural progenitor/stem cells (NSCs) as a viable path …

Immune rejection is an important obstacle to the use of allogeneic 'off-the-shelf'cells for
transplantation into immunocompetent patients. Genetic modification has emerged as a …